A Digital Publication for the Practicing Medical Specialist, Industry Executive & Investor

Cartessa Aesthetics’ Innovative Multi-Modality Treatment Leads Demand for Non-Invasive Body Procedures

Cartessa Aesthetics recently launched its newest device, PHYSIQ, leading the demand for the latest advancement in body treatments. The company notes PHYSIQ is a novel, dual-modality system that offers deep heat to target tissue and electrical muscle stimulation (EMS) to re-educate muscle – all from one device and in one session. An incredibly versatile device, PHYSIQ’s four applicators can be individually adjusted to tailor the energy and modality delivered to one or more body areas. Providers can select EMS or deep heat only or they have the unique ability to deliver both modalities sequentially within one treatment to maximize results and overall comfort. Treatments are hands-free, require no downtime and can be completely customized to meet each patient’s unique body goals.

Cartessa Aesthetics has made a name for itself by working with leading global aesthetic manufacturers to introduce best-in-class devices to the North American market. With PHYSIQ, aesthetic providers and patients have an optimized body treatment distinct from existing technology in the space.

“Optimizing clinical outcomes while providing best-in-class return on investment to physicians is at the core of Cartessa’s mission statement,” said Gabe Lubin, Cartessa Aesthetics Founder and CEO. “More people are favoring non-invasive procedures, even for treatments that address challenging body aesthetics. Patients want results, but without the pain and downtime that comes with surgery. Being able to offer a more complete patient treatment in a 30-minute session will offer providers a unique competitive advantage in the robust body market.”

The non-invasive body treatment category has erupted in the last decade. From 2011 to 2018 the number of procedures grew four-fold and it is estimated that by 2025, the North American market will hit $1.6 billion growing at an 8% compounded growth rate. PHYSIQ’s low consumable costs, minimal required staff-time and healthy patient demand makes it a premier investment opportunity for aesthetic providers. Sessions range from 24 to 36 minutes and the ability to address multiple body areas with multiple modalities in one session has established PHYSIQ as being truly unique in the body space.

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

The Evolut ™ FX+ TAVR system leverages market-leading valve performance with addition of larger windows to facilitate coronary access
The study was an analysis of AstraZeneca’s Phase 2 52-Week clinical trial of tralokinumab in patients with Idiopathic Pulmonary Fibrosis (IPF). The patient data from the trial was processed with Brainomix’s e-Lung tool. The tool is uniquely powered by the weighted reticulovascular score (WRVS), a novel biomarker that incorporates reticular opacities and vascular structures of the lung.
“Since the algorithm for matching patients with donors is changing across for all organs, this was a prime time to better understand whether transplant team decisions to accept a donated organ varied by patient race and gender,” she said. “We wanted to understand how the process of receiving a transplant after listing varied by race and gender, and the combination of the two, so that steps can be taken to make that process more equitable," said Khadijah Breathett, MD.
The Mount Sinai study found that primary care physicians’ approach reflects a dearth of evidence-based guidance for lung cancer screening shared decision-making in patients with complex comorbidities
This is the first ever transplantation of a genetically engineered porcine kidney into a living human recipient.

By using this website you agree to accept Medical Device News Magazine Privacy Policy